Drugs / DT2219ARL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00889408 | Dec 2013 → Jul 2014 | leukemia, lymphoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02370160 | Dec 2015 → Apr 2018 | B-cell acute lymphoblastic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-04-04 | GT Biopharma, Inc. | Regulatory Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550 gtbiopharma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-04-04 | GT Biopharma, Inc. | Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550 gtbiopharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT2219ARL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02370160 ↗ |
| Modality | Protein / enzyme biologic | “A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma” NCT00889408 ↗ |
| Route | Intravenous | “DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8” NCT00889408 ↗ |